文献速递糖尿病肥胖与代谢综合征性腺与生殖内分泌

青少年期MASLD合并PCOS增加成年期心血管代谢风险

MASLD coexisting with PCOS increases cardiometabolic risk.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

基于Raine研究199名社区女性青少年的纵向分析,采用更新诊断标准回顾判定14岁PCOS与17岁MASLD,并在27岁复评148人。结果显示,青少年期PCOS合并MASLD者在成年期胰岛素抵抗及残余脂蛋白胆固醇等指标更差;单纯PCOS或单纯MASLD未见同样预测作用。

要点

  • 青少年期PCOS合并MASLD提示成年期心血管代谢风险升高
  • 单纯PCOS不合并MASLD或肥胖,未预测未来胰岛素抵抗
  • 对PCOS青少年应评估MASLD以识别高危人群

核心结论

  • 青少年期PCOS合并MASLD而非单纯PCOS,增加成年期肥胖、胰岛素抵抗及不良心血管代谢表型的可能性。

研究设计与样本

  • Raine研究纵向队列,199名社区女性青少年完成PCOS与MASLD评估,27岁时148人完成人体测量及心血管与空腹血检测。
  • PCOS于14岁、MASLD于17岁按更新诊断标准回顾判定。

主要发现

  • 17岁时37人(18.6%)患MASLD,32人(16.1%)患PCOS,20人(10.1%)为PCOS不伴MASLD,142人(71.4%)两者均无。
  • PCOS青少年中12/32(37.5%)为PCOS+MASLD,与肥胖、更高血清残余脂蛋白胆固醇及游离和总睾酮、更低SHBG相关(P < .05)。
  • 27岁时青少年期PCOS+MASLD者(10/148)胰岛素抵抗更重,血清残余脂蛋白胆固醇及甘油三酯/高密度脂蛋白胆固醇比值更高(P < .05)。
  • 青少年期PCOS不伴MASLD或肥胖未预测未来胰岛素抵抗。

临床怎么用

  • 对PCOS青少年应考虑筛查MASLD,以识别成年期心血管代谢高危个体。
  • 评估PCOS青少年时关注肥胖、残余脂蛋白胆固醇及雄激素与SHBG水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: In women in their reproductive years, metabolic dysfunction-associated steatotic liver disease (MASLD) and polycystic ovary syndrome (PCOS) are the most common chronic liver and endocrine disorders, respectively. MASLD and PCOS are associated with longer-term risk of cardiometabolic complications. We aimed to determine whether PCOS coexisting with MASLD (PCOS + MASLD) predicts greater risk of future cardiometabolic adverse parameters than either condition alone after 10 years in a longitudinal study of adolescents in the Raine Study. METHOD: A total of 199 community-based female adolescents participating in the Raine Study had assessments for both PCOS and MASLD, including anthropometry, blood tests, and pelvic and abdominal ultrasound. Using updated diagnostic criteria, diagnoses of PCOS at age 14 years and MASLD at age 17 years, were retrospectively determined. At age 27 years, 148 participants had further anthropometry and cardiovascular and fasting blood assessments. RESULTS: At age 17 years, 37 (18.6%) had MASLD, 32 (16.1%) had PCOS, 20 (10.1%) had PCOS without MASLD, and 142 (71.4%) had neither. Among adolescents with PCOS, 12/32 (37.5%) had PCOS + MASLD, associated with obesity, higher serum remnant lipoprotein cholesterol, and free and total testosterone, but lower SHBG, compared with those with only MASLD, PCOS, or neither (P < .05 for all). By age 27 years, those with PCOS + MASLD (10/148) during adolescence were more insulin resistant and had higher serum remnant lipoprotein cholesterol and triglyceride/high-density lipoprotein cholesterol ratio (P < .05 for all), compared with those with only PCOS or MASLD or neither. PCOS without MASLD or obesity in adolescence did not predict future insulin resistance. CONCLUSION: PCOS + MASLD in adolescents, but not PCOS alone, increases the likelihood of obesity, insulin resistance and an adverse cardiometabolic phenotype during adulthood.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ayonrinde OT, Mori TA, Adams LA, et al. MASLD coexisting with PCOS increases cardiometabolic risk. J Clin Endocrinol Metab. 2026. PMID: 41527361. doi:10.1210/clinem/dgag008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。